儿童炎症性肠病的精准治疗

王歆琼; 许春娣

doi:10.12372/jcp.2022.22e1048

临床儿科杂志 >

2022 , Vol. 40 >Issue 11: 813 - 818

DOI: https://doi.org/10.12372/jcp.2022.22e1048

专家笔谈

儿童炎症性肠病的精准治疗

王歆琼 ,
许春娣

展开

上海交通大学医学院附属瑞金医院儿内科（上海 200025）

青年编委 王歆琼，博士，ORCID：0000-0003-0057-3653，医学博士，上海交通大学医学院附属瑞金医院儿内科副主任医师。兼任中华医学会儿科分会消化学组青年委员、中国妇幼保健协会妇幼微创专业委员会小儿消化胃肠学组青年委员、《临床儿科杂志》青年编委。主要从事儿童消化系统疾病的诊治和内镜操作以及相关疾病的基础研究工作。2017—2019年曾于美国犹他大学风湿免疫实验室访学。主持国家自然科学基金青年项目1项，参与国家级及省部级课题多项，国内外学术期刊上发表论文20余篇。

收稿日期: 2022-07-28

网络出版日期: 2022-11-10

基金资助

国家自然科学基金项目(81400588);国家自然科学基金项目(81741103);上海市嘉定区自然科学研究项目(JDKW-2020-0021)

收起

Precision treatment in pediatric inflammatory bowel disease

Xinqiong WANG ,
Chundi XU

Expand

Department of Pediatrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2022-07-28

Online published: 2022-11-10

Fold

摘要

我国儿童炎症性肠病（inflammatory bowel disease，IBD）的发病率不断上升，精准治疗可提高患儿的临床缓解及黏膜愈合率，提高儿童IBD的诊治水平。儿童IBD的精准治疗的发展主要基于对疾病发生发展认识的不断深入。生物制剂应用的不断优化可提高患儿的治疗效果，减轻经济负担。随着基因组学、转录组学、肠道微生态学及代谢组学等学科的发展及人工智能算法的协助，新的生物标志物不断被研究发现和应用。通过对儿童IBD精准化治疗的推动，IBD诊治策略将有新的改革和发展。

关键词： 精准治疗; 炎症性肠病; 生物制剂; 儿童

本文引用格式

王歆琼 , 许春娣 . 儿童炎症性肠病的精准治疗[J]. 临床儿科杂志, 2022 , 40(11) : 813 -818 . DOI: 10.12372/jcp.2022.22e1048

Abstract

The incidence of pediatric inflammatory bowel disease (IBD) in China rose these years. Precision treatment can improve the treatment of IBD and increase the remission rate. The development of precision treatment is mainly based on the in-depth understanding of the pathogenesis of IBD. The continuous optimization of biologic applications can improve the treatment outcome of children and reduce the economic burden. New biomarkers are constantly discovered and applied with the development of genomics, transcriptomics, gut microbiome, metabolomics, and artificial intelligence algorithms. Precision treatment will innovate treatment strategies in the near future.

Key words： precision treatment; inflammatory bowel disease; biologics; child

参考文献

[1]	Kuenzig ME, Fung SG, Marderfeld L, et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review[J]. Gastroenterology, 2022, 162(4): 1147-1159.
[2]	Wang XQ, Zhang Y, Xu CD, et al. Inflammatory bowel disease in Chinese children: a multicenter analysis over a decade from Shanghai[J]. Inflamm Bowel Dis, 2013, 19(2): 423-428.
[3]	中华医学会儿科学分会消化学组,中华医学会儿科学分会临床营养学组. 儿童炎症性肠病诊断和治疗专家共识[J]. 中华儿科杂志, 2019, 57(7): 501-507.
[4]	Solberg IC, Vatn MH, Høie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study[J]. Clin Gastroenterol Hepatol, 2007, 5(12): 1430-1438.
[5]	Verstockt B, Noor NM, Marigorta UM, et al. Results of the seventh scientific workshop of ECCO: precision medicine in IBD-disease outcome and response to therapy[J]. J Crohns Colitis, 2021, 15(9): 1431-1442.
[6]	van Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update[J]. J Crohns Colitis, 2020, 7: 1-24.
[7]	Siegel CA, Horton H, Siegel LS, et al. A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables[J]. Aliment Pharmacol Ther, 2016, 43(2): 262-271.
[8]	Billiet T, Papamichael K, de Bruyn M, et al. A matrix-based model predicts primary response to infliximab in Crohn's disease[J]. J Crohns Colitis, 2015, 9(12): 1120-1126.
[9]	Singh N, Rabizadeh S, Jossen J, et al. Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease[J]. Inflamm Bowel Dis, 2016, 22(9): 2121-2126.
[10]	Fang S, Song Y, Zhang C, et al. Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review[J]. BMC Pediatr, 2022, 22(1): 175.
[11]	Dulai PS, Boland BS, Singh S, et al. Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn's disease[J]. Gastroenterology, 2018, 155(3): 687-695.
[12]	Dulai PS, Singh S, Vande Casteele N, et al. Development and validation of clinical scoring tool to predict outcomes of treatment with vedolizumab in patients with ulcerative colitis[J]. Clin Gastroenterol Hepatol, 2020, 18(13): 2952-2961.
[13]	Kakiuchi T, Yoshiura M. Japanese pediatric patient with moderately active ulcerative colitis successfully treated with ustekinumab: a case report[J]. Medicine (Baltimore), 2022, 101(7): e28873.
[14]	Fujita Y, Sugaya T, Tanaka T, et al. Ustekinumab as the first biological agent for Crohn's disease in a 10-year-old girl[J]. Tohoku J Exp Med, 2021, 255(1): 57-60.
[15]	Dolinger MT, Spencer EA, Lai J, et al. Dual biologic and small molecule therapy for the treatment of refractory pediatric inflammatory bowel disease[J]. Inflamm Bowel Dis, 2021, 27(8): 1210-1214.
[16]	许旭, 肖园, 邱文娟, 等. 糖原累积病Ⅰb型并发克罗恩病一例[J]. 中华儿科杂志, 2017, 55(2): 144-145.
[17]	Papamichael K, Chachu KA, Vajravelu RK, et al. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab[J]. Clin Gastroenterol Hepatol, 2017, 15(10): 1580-1588.
[18]	Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease[J]. Gastroenterology, 2015, 148(7): 1320-1329.
[19]	Nguyen NH, Solitano V, Vuyyuru SK, et al. Proactive therapeutic drug monitoring versus conventional management for inflammatory bowel diseases: a systematic review and meta-analysis[J]. Gastroenterology, 2022, 24(22): 670-679.
[20]	Alsoud D, Vermeire S, Verstockt B. Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?[J]. Curr Opin Pharmacol, 2020, 55: 17-30.
[21]	Colombel JF, Adedokun OJ, Gasink C, et al. Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis[J]. Clin Gastroenterol Hepatol, 2019, 17(8): 1525-1532.
[22]	Warner B, Johnston E, Arenas-Hernandez M, et al. A practical guide to thiopurine prescribing and monitoring in IBD[J]. Frontline Gastroenterol, 2018, 9(1): 10-15.
[23]	Bak-Drabik K, Adamczyk P, Duda-Wronska J, et al. Usefulness of measuring thiopurine metabolites in children with inflammatory bowel disease and autoimmunological hepatitis, treated with azathioprine[J]. Gastroenterol Res Pract, 2021, 2021: 9970019.
[24]	Simsek M, Deben DS, Horjus CS, et al. Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies[J]. Aliment Pharmacol Ther, 2019, 50(1): 54-65.
[25]	Moriyama T, Nishii R, Perez-Andreu V, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity[J]. Nat Genet, 2016, 48(4): 367-373.
[26]	Heap GA, Weedon MN, Bewshea CM, et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants[J]. Nat Genet, 2014, 46(10): 1131-1134.
[27]	Verstockt B, Parkes M, Lee JC. How do we predict a patient's disease course and whether they will respond to specific treatments?[J]. Gastroenterology, 2022, 162(5): 1383-1395.
[28]	Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial[J]. Lancet, 2017, 390(10114): 2779-2789.
[29]	West NR, Hegazy AN, Owens BMJ, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease[J]. Nat Med, 2017, 23(5):579-589.
[30]	Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study[J]. Lancet, 2017, 389(10080): 1710-1718.
[31]	Martin JC, Chang C, Boschetti G, et al. Single-cell analysis of Crohn's disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy[J]. Cell, 2019, 178(6): 1493-1508.
[32]	Nayar S, Morrison JK, Giri M, et al. A myeloid-stromal niche and gp130 rescue in NOD2-driven Crohn's disease[J]. Nature, 2021, 593(7858): 275-281.
[33]	Morilla I, Uzzan M, Laharie D, et al. Colonic MicroRNA profiles, identified by a deep learning algorithm, that predict responses to therapy of patients with acute severe ulcerative colitis[J]. Clin Gastroenterol Hepatol, 2019, 17(5): 905-913.
[34]	Wang X, Xiao Y, Xu X, et al. Characteristics of fecal microbiota and machine learning strategy for fecal invasive biomarkers in pediatric inflammatory bowel disease[J]. Front Cell Infect Microbiol, 2021, 11: 711884.
[35]	Wang Y, Gao X, Ghozlane A, et al. Characteristics of faecal microbiota in paediatric Crohn's disease and their dynamic changes during infliximab therapy[J]. J Crohns Colitis, 2018, 12(3): 337-346.
[36]	Takaishi H, Matsuki T, Nakazawa A, et al. Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease[J]. Int J Med Microbiol, 2008, 298(5-6): 463-472.
[37]	Borren NZ, Plichta D, Joshi AD, et al. Multi-"-Omics" profiling in patients with quiescent inflammatory bowel disease identifies biomarkers predicting relapse[J]. Inflamm Bowel Dis, 2020, 26(10): 1524-1532.

Options

文章导航

模态框（Modal）标题

摘要

本文引用格式

Abstract

参考文献